Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:01:38 2024-04-25 am EDT			5-day change	1st Jan Change
7.49 ^USD	-5.67%		+2.23%	-23.28%

Apr. 18	Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	MT
Apr. 16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT

Recursion Pharma Gets FDA Fast-Track Designation for Polyp Treatment

April 11, 2022 at 06:36 am EDT

By Rob Curran

Recursion Pharmaceuticals Inc. received fast-track designation from the U.S. Food and Drug Administration for a polyp treatment, the company said Monday.

The Salt Lake City biotech company received the approval for the accelerated development of its REC-4881 pill for the treatment of familial adenomatous polyposis in patients who have previously undergone certain colon surgeries. The FDA grants fast-track status to treatments for significant unmet medical needs.

Recursion Pharmaceuticals expects to enroll patients for a Phase 2 trial of REC-4881 to evaluate safety, pharmacokinetics and efficacy in familial adenomatous polyposis patients in the third quarter.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

04-11-22 0836ET

Latest news about Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	Apr. 18	MT
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	Apr. 16	MT
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer	Apr. 16	CI
Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing	Mar. 15	MT
Recursion Pharmaceuticals to Open London Office	Mar. 11	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	Feb. 28	MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q4 Revenue $10.9M	Feb. 27	MT
Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer	Feb. 27	CI
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Recursion Pharmaceuticals Insider Sold Shares Worth $507,985, According to a Recent SEC Filing	Feb. 16	MT
Nvidia Discloses Stake in Tech Firms, Causing Shares to Rise	Feb. 15	MT
Nvidia Discloses Investment Stakes in AI Firms; Shares Jump	Feb. 15	MT
Let's move forward	Feb. 15
Arm, SoundHound AI shares jump as Nvidia builds stake	Feb. 15	RE
Recursion Pharmaceuticals Insider Sold Shares Worth $444,981, According to a Recent SEC Filing	Feb. 09	MT
Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor	Feb. 07	CI
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	Jan. 26	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $517,508, According to a Recent SEC Filing	Jan. 19	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $396,214, According to a Recent SEC Filing	Jan. 12	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $273,202, According to a Recent SEC Filing	Jan. 12	MT
Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference	Jan. 08	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 04	MT

Chart Recursion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Recursion Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.94 USD

Average target price

13 USD

Spread / Average Target

+63.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RECURSION PHARMACEUTICALS, INC.	-23.28%	1.89B
VERTEX PHARMACEUTICALS INCORPORATED	-2.24%	104B
REGENERON PHARMACEUTICALS, INC.	+1.66%	97.42B
ARGENX SE	+0.52%	22.2B
BIONTECH SE	-17.57%	21.23B
GENMAB A/S	-10.58%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-18.15%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.61%	13.98B
SAREPTA THERAPEUTICS, INC.	+27.19%	11.66B

Bio Therapeutic Drugs